Rehaneo has secured Fremman Capital as a majority shareholder, aiming to enhance its outpatient rehabilitation services and drive growth through strategic acquisitions in a fragmented market.
Information on the Target
Rehaneo, established in 2020, is a prominent provider of outpatient rehabilitation, aftercare, prevention, and occupational health management in Germany. The company has experienced significant growth since its inception, particularly during the COVID-19 pandemic, evolving into one of the top three providers in its sector. Founders Bruno Crone and Christoph Dühr, who maintain substantial stakes in the business, continue to lead the organization while effectively managing its expansion.
Under the guidance of Gimv, the previous majority shareholder, rehaneo has successfully integrated 13 companies across 23 locations nationwide. Its recent establishment of a new center in Göttingen showcases its commitment to accessible rehabilitation services. Currently, rehaneo employs over 1,000 professionals dedicated to serving more than 80,000 patients annually across various offerings, including outpatient rehabilitation, aftercare, physiotherapy, and occupational therapy.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Germany
In Germany, the outpatient rehabilitation industry is witnessing a strong demand driven by patient preferences for consistent care within familiar environments. Compared to inpatient care, outpatient rehabilitation services a
Similar Deals
STARTIME MED GmbH → Kröger Medical Personaldienstleistungen GmbH
2025
Elliott Advisors (UK) Limited → SYNLAB AG
2024
PINOVA Capital GmbH → NEUROMEDEX
2024
NORD Holding → ABJ alive GmbH
2024
aesco solutions group → seleon GmbH
2024
Novum Capital → HECHT Contactlinsen GmbH
2024
Fremman Capital
invested in
rehaneo
in 2024
in a Management Buyout / Buy-In (MBO) deal